Library · Metabolic & weight · Investigational for treating obesity, potentially in combination with GLP-1 agonists.
ZP6590 (GIP agonist)
ZP-6590, ZP 6590, GIP receptor agonist ZP6590
An investigational long-acting GIP receptor agonist in preclinical development, with first-in-human trials planned. Preclinical data suggest it enhances weight loss from GLP-1 monotherapy and reduces nausea, positioning it as a potential combination-therapy component for obesity.
Research score 40/100. Reference only, not a dose.
- GIP Agonist
- Blood Sugar Control
- Appetite Suppression
- Metabolic Enhancement
- Insulin Regulation
- US status
- Investigational
- Approval
- Preclinical Development (First-in-human clinical trials planned).
- Evidence
- Animal + In Vitro Studies
- Research score
- 40 / 100
- Indication
- Investigational - Obesity (in combination with GLP-1 agonists).
- Origin
- Denmark
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
Selectively binds pancreatic β-cell GIP receptors, activating adenylyl cyclase through Gs-protein coupling to raise cAMP and enhance glucose-dependent insulin secretion and β-cell function; also affects fat storage and energy balance in adipose tissue and influences nutrient absorption.
Safety file
No human safety data are available; general GLP-1/GIP agonist concerns include GI side effects, dehydration, kidney function decline, and hypoglycemia risk.
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Dehydration
- Renal function decline
- Hypoglycemia risk
- Acute pancreatitis (general GLP-1/GIP agonist side effects; specific ZP6590 human data lacking)